In this study, we aimed to investigate: i) the expression levels of XB130 in four different CCA cell lines (KKU-100, KKU-213A, KKU-213C, and KKU-023) compared to an immortalized cholangiocyte cell line (MMNK1); ii) the effects of decreased XB130 expression on cell proliferation, cell migration and invasion in XB130-expressing KKU-213A cells; iii) the expression levels of XB130 in CCA tissues using immunohistochemistry; and iv) the relationship between the XB130 expression levels with the clinicopathological features and survival rates of CCA patients. The gene discussed is AFAP1L2; the disease is cholangiocarcinoma.